ceritinib (BioDeep_00000177165)
human metabolite blood metabolite
代谢物信息卡片
5-chloro-N2-[5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl]-N4-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine
化学式: C28H36ClN5O3S (557.2227)
中文名称: 色瑞替尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C)OC1=C(NC2=NC(NC3=CC=CC=C3S(=O)(=O)C(C)C)=C(Cl)C=N2)C=C(C)C(=C1)C1CCNCC1
InChI: InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)
描述信息
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01ED - Anaplastic lymphoma kinase (alk) inhibitors
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C141136 - ALK Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
D000970 - Antineoplastic Agents
同义名列表
7 个代谢物同义名
5-chloro-N2-[5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl]-N4-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine; 5-chloro-N2-[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]-N4-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine; 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; Ceritinibum; ceritinib; ZYKADIA; LDK378
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:78432
- PubChem: 57379345
- HMDB: HMDB0249821
- DrugBank: DB09063
- ChEMBL: CHEMBL2403108
- Wikipedia: Ceritinib
- CAS: 1032900-25-6
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Markus Fischer, Meike Luck, Max Werle, Alexander Vogel, Mohammad Bashawat, Kai Ludwig, Holger A Scheidt, Peter Müller. The small-molecule kinase inhibitor ceritinib, unlike imatinib, causes a significant disturbance of lipid membrane integrity: A combined experimental and MD study.
Chemistry and physics of lipids.
2023 11; 257(?):105351. doi:
10.1016/j.chemphyslip.2023.105351. [PMID: 37863350] - Yuyao Luo, Zhe Zhang, XuanZhu Guo, Xuemei Tang, Sijie Li, Guotao Gong, Shun Gao, Yan Zhang, Sheng Lin. Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis.
Lung cancer (Amsterdam, Netherlands).
2023 Aug; 184(?):107319. doi:
10.1016/j.lungcan.2023.107319. [PMID: 37597303] - Bei Zheng, Hong Jiang, Wenjuan Yang, Ying Li, Bingqing Liang, Jun Zhu, Nanmei Chen, Miao Chen, Meiling Zhang. A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer.
Cancer medicine.
2023 08; 12(15):15983-15997. doi:
10.1002/cam4.6241. [PMID: 37334877] - Laura Q M Chow, Fabrice Barlesi, Erin M Bertino, Martin J van den Bent, Heather A Wakelee, Patrick Y Wen, Chao-Hua Chiu, Sergey Orlov, Rita Chiari, Margarita Majem, Mark McKeage, Chong-Jen Yu, Pilar Garrido, Felipe K Hurtado, Pilar Cazorla Arratia, Yuanbo Song, Fabrice Branle, Michael Shi, Dong-Wan Kim. ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2022 06; 28(12):2506-2516. doi:
10.1158/1078-0432.ccr-21-1838. [PMID: 35091443] - Shwetal Mehta, Roberto Fiorelli, Xun Bao, Chelsea Pennington-Krygier, Alanna Derogatis, Seongho Kim, Wonsuk Yoo, Jing Li, Nader Sanai. A Phase 0 Trial of Ceritinib in Patients with Brain Metastases and Recurrent Glioblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2022 01; 28(2):289-297. doi:
10.1158/1078-0432.ccr-21-1096. [PMID: 34702773] - Christos Fountzilas, Alex Adjei, Mateusz Opyrchal, Rachel Evans, Mohammad Ghasemi, Kristopher Attwood, Adrienne Groman, Wiam Bshara, Andrew Goey, John Wilton, Wen Wee Ma, Renuka Iyer. A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors.
International journal of cancer.
2021 12; 149(12):2063-2074. doi:
10.1002/ijc.33754. [PMID: 34319586] - Yuji Mukai, Azusa Wakamoto, Tae Hatsuyama, Tatsunari Yoshida, Hideki Sato, Akihisa Fujita, Nobuo Inotsume, Takaki Toda. An Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of Afatinib, Alectinib, Ceritinib, Crizotinib, Dacomitinib, Erlotinib, Gefitinib, and Osimertinib in Human Serum.
Therapeutic drug monitoring.
2021 12; 43(6):772-779. doi:
10.1097/ftd.0000000000000895. [PMID: 33871406] - Hadir M Maher, Aliyah Almomen, Nourah Z Alzoman, Shereen M Shehata, Ashwaq A Alanazi. Development and validation of UPLC-MS/MS method for the simultaneous quantification of anaplastic lymphoma kinase inhibitors, alectinib, ceritinib, and crizotinib in Wistar rat plasma with application to bromelain-induced pharmacokinetic interaction.
Journal of pharmaceutical and biomedical analysis.
2021 Sep; 204(?):114276. doi:
10.1016/j.jpba.2021.114276. [PMID: 34325247] - Zheng Li, Ming Guo, Meng Cao, Tianming Zhao, Mingzhu Li, Xin Zhai. Discovery and antitumor activity of Benzo[d]imidazol-containing 2,4-diarylaminopyrimidine analogues as ALK inhibitors with mutation-combating effects.
Bioorganic & medicinal chemistry.
2021 05; 37(?):116108. doi:
10.1016/j.bmc.2021.116108. [PMID: 33756437] - Dongsheng Yue, Juanjuan Qian, Zhipeng Chen, Bin Zhang, Peng Chen, Lei Zhang, Jingjing Li, Henghui Zhang, Changli Wang. Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with ROS1-rearranged lung adenocarcinoma.
Journal for immunotherapy of cancer.
2021 02; 9(2):. doi:
10.1136/jitc-2020-001967. [PMID: 33558279] - G D Marijn Veerman, Peter de Bruijn, Anne-Marie C Dingemans, Ron H J Mathijssen, Stijn L W Koolen. To quantify the small-molecule kinase inhibitors ceritinib, dacomitinib, lorlatinib, and nintedanib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry.
Journal of pharmaceutical and biomedical analysis.
2021 Jan; 193(?):113733. doi:
10.1016/j.jpba.2020.113733. [PMID: 33217707] - Jie He, Zhihui Zhou, Xin Sun, Zunhua Yang, Pengwu Zheng, Shan Xu, Wufu Zhu. The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation.
European journal of medicinal chemistry.
2021 Jan; 210(?):112995. doi:
10.1016/j.ejmech.2020.112995. [PMID: 33243531] - Xiaoyun Lu, Jeff B Smaill, Ke Ding. Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations.
Journal of medicinal chemistry.
2020 10; 63(19):10726-10741. doi:
10.1021/acs.jmedchem.0c00507. [PMID: 32432477] - Yuke Tian, Tian Tian, Ping Yu, Li Ren, Youling Gong, Wenxiu Yao, Xi Zhang, Jun Yin, Lang He, Li Chen, Ke Wang, Meijuan Huang, Juan Li. [Safety and Preliminary Efficacy of Ceritinib 450 mg with Food in Chinese ALK-positive Non-small Cell Lung Cancer].
Zhongguo fei ai za zhi = Chinese journal of lung cancer.
2020 Aug; 23(8):655-661. doi:
10.3779/j.issn.1009-3419.2020.102.33. [PMID: 32838488] - Ping Du, Yin Guan, Zhuoling An, Pengfei Li, Lihong Liu. A selective and robust UPLC-MS/MS method for the simultaneous quantitative determination of anlotinib, ceritinib and ibrutinib in rat plasma and its application to a pharmacokinetic study.
The Analyst.
2019 Sep; 144(18):5462-5471. doi:
10.1039/c9an00861f. [PMID: 31380858] - Alexandra Russo, Claudia Paret, Francesca Alt, Jürgen Burhenne, Margaux Fresnais, Wolfgang Wagner, Martin Glaser, Hannah Bender, Sabrina Huprich, Patrick N Harter, Katharina Filipski, Nadine Lehmann, Nora Backes, Lea Roth, Larissa Seidmann, Clemens Sommer, Marc A Brockmann, Torsten Pietsch, Marie A Neu, Arthur Wingerter, Jörg Faber. Ceritinib-Induced Regression of an Insulin-Like Growth Factor-Driven Neuroepithelial Brain Tumor.
International journal of molecular sciences.
2019 Aug; 20(17):. doi:
10.3390/ijms20174267. [PMID: 31480400] - Takeshi Hirota, Shota Muraki, Ichiro Ieiri. Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.
Clinical pharmacokinetics.
2019 04; 58(4):403-420. doi:
10.1007/s40262-018-0689-7. [PMID: 29915924] - Taizou Hirano, Akira Koarai, Tomohiro Ichikawa, Teruyuki Sato, Takashi Ohe, Masakazu Ichinose. Possible involvement of interleukin-18 in the pathology of hepatobiliary adverse effects related to treatment with ceritinib.
BMC cancer.
2018 Oct; 18(1):995. doi:
10.1186/s12885-018-4913-5. [PMID: 30340555] - Chengwei Zhang, Xiao-Ran Han, Xiaobao Yang, Biao Jiang, Jing Liu, Yue Xiong, Jian Jin. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
European journal of medicinal chemistry.
2018 May; 151(?):304-314. doi:
10.1016/j.ejmech.2018.03.071. [PMID: 29627725] - Byoung Chul Cho, Dong-Wan Kim, Alessandra Bearz, Scott A Laurie, Mark McKeage, Gloria Borra, Keunchil Park, Sang-We Kim, Marwan Ghosn, Andrea Ardizzoni, Evaristo Maiello, Alastair Greystoke, Richard Yu, Karen Osborne, Wen Gu, Jeffrey W Scott, Vanessa Q Passos, Yvonne Y Lau, Anna Wrona. ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2017 09; 12(9):1357-1367. doi:
10.1016/j.jtho.2017.07.005. [PMID: 28729021] - Andrew C Wood, Kateryna Krytska, Hannah T Ryles, Nicole R Infarinato, Renata Sano, Theodore D Hansel, Lori S Hart, Frederick J King, Timothy R Smith, Edward Ainscow, Kathryn B Grandinetti, Tove Tuntland, Sunkyu Kim, Giordano Caponigro, You Qun He, Shiva Krupa, Nanxin Li, Jennifer L Harris, Yaël P Mossé. Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2017 Jun; 23(11):2856-2868. doi:
10.1158/1078-0432.ccr-16-1114. [PMID: 27986745] - Christian Lanshoeft, Olivier Heudi, Marc Raccuglia, Luc Alexis Leuthold, Franck Picard, Olivier Kretz. Ultrafast quantitative MS-based method for ceritinib analysis in human plasma samples from clinical trial.
Bioanalysis.
2015; 7(4):425-35. doi:
10.4155/bio.14.292. [PMID: 25747762] - Olivier Heudi, Denise Vogel, Yvonne Y Lau, Franck Picard, Olivier Kretz. Liquid chromatography tandem mass spectrometry method for the quantitative analysis of ceritinib in human plasma and its application to pharmacokinetic studies.
Analytical and bioanalytical chemistry.
2014 Nov; 406(28):7389-96. doi:
10.1007/s00216-014-8125-9. [PMID: 25258279]
